In particular, plasma MYCN/NAGK ratio was significantly higher in NB patients with serum NSE more than 370 ng·mL−1 and serum LDH more than 1500 IU·L−1 than those with NSE less than 370 ng·mL−1 and LDH less than 1500 IU·L−1, 26.17 (median CI 95%, 1.71, 60.76) vs 1.32 (median CI 95%, 1.00, 1.57), 81.43 (median CI 95%, 40.74, 149.6) vs 1.54 (median CI 95%, 1.30, 1.73), or vs 1.13 (median CI 95%, 0.89, 1.54), respectively. The gene discussed is ENO2; the disease is neuroblastoma.